Cited 23 times in
Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강화평 | - |
dc.contributor.author | 방승민 | - |
dc.contributor.author | 정문재 | - |
dc.date.accessioned | 2019-02-14T01:51:50Z | - |
dc.date.available | 2019-02-14T01:51:50Z | - |
dc.date.issued | 2018 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/167262 | - |
dc.description.abstract | AIM: To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS: This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with unresectable PC, who showed disease progression during GEM-based chemotherapy were enrolled. All patients were administered FOLFIRINOX with reduced irinotecan and oxaliplatin (RIO; irinotecan 120 mg/m2 and oxaliplatin 60 mg/m2), which was set according to the phase I study of FOLFIRINOX. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), adverse events were evaluated. Additionally, changes in quality of life (QoL) were assessed using a questionnaire on QoL. RESULTS: Between August 2015 and May 2016, a total of 48 patients were enrolled. The median follow-up time was 259 d with a median of 8.5 cycles. The ORR and DCR were 18.8% and 62.5%, respectively, including one patient who showed complete remission. The median PFS was 5.8 mo [95% confidence interval (CI): 3.7-7.9] and median OS was 9.0 mo (95%CI: 6.4-11.6). Neutropenia (64.6%) was the most common grade 3-4 adverse event, followed by febrile neutropenia (16.7%). Although 14.6% of patients experienced grade 3 fatigue, most non-hematologic AEs were under grade 2. In the QoL analysis, the global health status score before treatment was not different from the score at the last visit after treatment (45.43 ± 22.88 vs 48.66 ± 24.14, P = 0.548). CONCLUSION: FOLFIRINOX with RIO showed acceptable toxicity and promising efficacy for GEM-refractory unresectable PC. However, this treatment requires careful observation of treatment-related hematologic toxicities. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Baishideng Publishing Group | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Moon Jae Chung | - |
dc.contributor.googleauthor | Huapyong Kang | - |
dc.contributor.googleauthor | Ho Gak Kim | - |
dc.contributor.googleauthor | Jong Jin Hyun | - |
dc.contributor.googleauthor | Jun Kyu Lee | - |
dc.contributor.googleauthor | Kwang Hyuck Lee | - |
dc.contributor.googleauthor | Myung Hwan Noh | - |
dc.contributor.googleauthor | Dae Hwan Kang | - |
dc.contributor.googleauthor | Sang Hyub Lee | - |
dc.contributor.googleauthor | Seungmin Bang | - |
dc.contributor.googleauthor | Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer | - |
dc.identifier.doi | 10.4251/wjgo.v10.i12.505 | - |
dc.contributor.localId | A00100 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A03602 | - |
dc.relation.journalcode | J03571 | - |
dc.identifier.eissn | 1948-5204 | - |
dc.identifier.pmid | 30595804 | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Clinical Trial, Phase II | - |
dc.subject.keyword | FOLFIRINOX | - |
dc.subject.keyword | Gemcitabine refractory | - |
dc.subject.keyword | Pancreatic cancer | - |
dc.contributor.alternativeName | Kang, Huapyong | - |
dc.contributor.affiliatedAuthor | 강화평 | - |
dc.contributor.affiliatedAuthor | 방승민 | - |
dc.contributor.affiliatedAuthor | 정문재 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 505 | - |
dc.citation.endPage | 515 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, Vol.10(12) : 505-515, 2018 | - |
dc.identifier.rimsid | 61467 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.